Our Clinical Candidate

Mocravimod is a modulator of sphingosine-1-phosphate (S1P) receptors. Priothera is developing mocravimod in AML with the aim of enhancing the curative potential of Hematopoietic Stem Cell Transplantation (HSCT). Promising early clinical results have revealed that mocravimod has the potential to rebalance the patient’s immune system by decoupling Graft-versus-Host Disease (GvHD)  from Graft-versus-Leukemia  (GvL), preventing the first and preserving the latter.

Contact Us

Priothera Ltd
88 Harcourt Street, Dublin 2, D02 DK18, Ireland

Priothera Ltd
88 Harcourt Street, Dublin 2,
D02 DK18, Ireland

Priothera SAS France
9 Rue du Temple, Saint Louis, 68300, France